TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hua Medicine ( (HK:2552) ) has provided an update.
Hua Medicine announced a significant increase in sales and revenue for the first half of 2025, driven by the successful transition to self-commercialization of HuaTangNing. The company reported a 108% increase in HuaTangNing sales and a 112% rise in revenue, attributed to broader hospital coverage and inclusion in China’s National Reimbursement Drug List. The termination of an exclusive promotion agreement with Bayer allowed Hua Medicine to recognize substantial deferred income, bolstering its financial position. The company is also advancing post-marketing studies and expanding its product registration in Hong Kong, aiming to enhance its market footprint and explore new clinical insights into diabetes management.
The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.
More about Hua Medicine
Hua Medicine is a pharmaceutical company focused on developing innovative therapies for diabetes management. Its primary product, HuaTangNing, is a glucose kinase activator aimed at improving glucose control in diabetic patients. The company is expanding its market presence across Greater China and Southeast Asia.
Average Trading Volume: 10,287,744
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.49B
For a thorough assessment of 2552 stock, go to TipRanks’ Stock Analysis page.